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Abstract. Working memory deficits have been found in Huntington’s disease (HD) and in a small group of premanifest (PreHD)
gene-carriers. However, the nature and extent of these deficits are unknown. In a large cross-sectional study, we aimed to
determine the degree of visuospatial working memory dysfunction across multiple stages of HD. Specifically, visuospatial
working memory capacity and response times across various degrees of difficulty were examined, as well as the relationship
between visuospatial working memory and motor dysfunction. We examined 62 PreHD-A gene-carriers (>10.8 years from
estimated disease onset), 58 PreHD-B gene-carriers (<10.8 years from estimated disease onset), 77 stage-1 HD patients (HD1),
44 stage-2 HD patients (HD2), and 122 healthy controls. Participants viewed coloured squares (in sets of 3, 5 and 7) on a screen
and were to decide whether on a subsequent screen the encircled square has changed colour. Accuracy and response times were
recorded. Compared to controls, significant group differences in visuospatial working memory capacity (accuracy) were seen
in PreHD-B, HD1 and HD2 groups across the difficulty levels. Significant group differences on response times were found
for all groups (PreHD-A to HD2) compared to controls; the most difficult level producing the only group difference in speed
between PreHD-A and controls. Accuracy and speed were positively correlated only in the HD groups. These findings suggest
that visuospatial working memory impairments are detectable in both premanifest and manifest HD; the manifest HD showed
evidence for a “worse-worse phenomenon” whereby reductions were present in both motor speed and accuracy.
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Huntington’s disease (HD) is an autosomal domi-
nant neurodegenerative disease, which is characterised
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by progressive motor, psychiatric and cognitive symp-
toms and signs [1–4]. The mean age of disease
diagnosis is between 35 and 45 years [4]. Individuals
at risk of carrying the HD gene can be tested. Those
who are found to have the gene but not to have clinical
disease (i.e., motor) signs are referred to as premanifest
gene-carriers. Many studies investigating cognition in
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HD have demonstrated progressive cognitive decline
resulting in dementia [5, 6]. Cognitive decline is also
detectable in the premanifest gene-carriers across a
number of domains, including executive functions,
memory, emotion recognition and psychomotor func-
tions [7–9].
Working memory is a topic of recent attention as a
possible marker for disease state in HD [10, 11]. Many
day-to-day activities require retention, integration and
manipulation of either verbally or visually presented
information, referred to as verbal or visual (or visu-
ospatial) working memory [12]. Poor working memory
has been described as part of the disease course of
HD. In particular, several cross-sectional studies have
demonstrated that HD patients show poorer spatial or
visual working memory in comparison to controls [9,
11, 13–15]. Visual working memory was also found
to decline in patients with HD over 12-, 24- and 42-
months [2, 3, 16].
Studies of premanifest gene-carriers have identi-
fied mild-to-moderate cognitive deficits in a range of
domains, including attention, memory, psychomotor
speed and executive functioning, which are among
the first cognitive functions to show decline in the
premanifest phase [17–23]. With regard to working
memory, the evidence in premanifest HD is unclear.
Some studies have reported impairments in both verbal
and visual working memory [17, 24]. However, others
have suggested that premanifest HD do not differ from
controls in either visual or verbal working memory [19,
25]. In addition, although evidence regarding working
memory decline in premanifest HD is limited, it does
suggest that working memory, in particular visuospa-
tial working memory, may be among the first cognitive
functions to show decline in the premanifest phase [3,
10].
Working memory is implicated in complex brain
networks whereby integrated signals received by the
parietal cortex, are then projected onto the frontos-
triatal brain circuits which then subsequently drive
motor responses [26–28]. The underlying brain regions
associated with working memory, namely the caudate
nucleus and putamen which lie within the frontostri-
atal brain circuits, are also among the primary regions
implicated in the cognitive dysfunction, neurobiol-
ogy and aetiology of HD [29–33]. Specifically, brain
activation studies involving working memory perfor-
mances in premanifest HD reported reduced functional
connectivity in regions of the frontostriatal brain cir-
cuit such as the putamen and prefrontal cortex [34,
35], as well as reduced brain activity during elec-
troencephalograph measures [36], when compared to
controls. These changes were observed even in the
absence of behavioural differences in working mem-
ory task performance. Structural evidence has shown
that brain atrophy in premanifest gene-carriers devel-
ops prior to disease diagnosis, and it progresses during
the disease course, with the most profound and earli-
est changes found in the caudate nucleus and putamen
[9, 37–39]. Given that both cognitive dysfunction and
abnormal neurobiology have been observed in HD
including in premanifest gene-carriers who are more
than ten years before estimated disease onset [9, 20,
22, 39], it can be expected that deficits in visual work-
ing memory would develop as the disease progresses
(and the brain regions deteriorate).
In addition, motor functioning overlaps with cogni-
tive functioning, in that both are implicated in brain
structures such as the basal ganglia [40], and cogni-
tive performance is measured through motor outputs
such as verbal or button-based responses. The most
sensitive assessments of early cognitive changes in
HD are those with a substantial psychomotor speed
component [8, 9, 22, 41]. Therefore, to better under-
stand how HD affects cognition, it is important to
distinguish, where possible, the impact of motor func-
tioning on cognitive measures. Also, as we move
toward treatment-focused studies in HD, it is neces-
sary to understand the progression of cognitive deficits
in relation to motor dysfunction. This is important
since patient groups are often defined in terms of
their level of motor deficits. The distinction between
premanifest and manifest HD is made based on the
level of motor abnormalities. For premanifest groups,
stringent exclusion of motor deficits can facilitate dis-
tinctions between motor and cognitive disease effects,
although subtle motor changes are not eliminated by
this approach. Cognitive tasks that require minimal
motor responses are also desirable in this respect.
The background presence of motor slowing also
complicates the interpretation of cognitive testing
in HD. One approach, to disentangle the motor
and cognitive effects, is to examine the relation-
ship between performance accuracy and response
times. This relationship is often observed as a ‘speed-
accuracy trade-off’, which refers to a strategy whereby
participants use a slower, more cautious approach to
ensure the accuracy of their performance. Conversely,
faster responses may lead to greater inaccuracy due to
being less careful or less cautious. We hypothesised
that HD gene-carriers may slow their responses as a
compensatory strategy in order to maintain satisfactory
cognitive performance. Because we wanted to exam-
ine whether speed-accuracy trade-offs would appear in
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relation to working memory performance in HD, we
selected a task in which these two aspects of perfor-
mance could be examined separately, allowing their
relationship to be studied in the context of HD.
Using data obtained from a large multisite interna-
tional and observational study known as TRACK-HD
[3, 9], the current study aimed to determine, using
a more detailed analysis, the degree of visuospatial
working memory dysfunction in HD. Previous publi-
cations from TRACK-HD [2, 3, 9] have reported on
data from the current working memory task; however
this involved reporting only a single primary outcome
variable (i.e., working memory capacity) with differ-
ent group comparisons and using different statistical
analysis techniques. Specifically, we aimed to examine
visuospatial working memory impairments relating to
working memory capacity and response times across
multiple disease stages including both premanifest
gene-carriers and those in early stage HD. In addi-
tion, and unlike the previous publications, we wanted
to examine visuospatial working memory function in
HD across different levels of task complexity. Further-
more, we wanted to distinguish between cognitive and
motor influences in order to clarify whether working
memory itself, rather than just the motor expression of
this cognitive function, is affected in HD. By address-
ing these aims, we can obtain evidence regarding the
possibility that a working memory task may be suit-
able as a marker for cognitive deterioration in early
diagnosed or even premanifest HD.
METHODS
Participants
Three hundred and sixty-six subjects were studied
as part of the TRACK-HD study [1, 3, 9]. Of these, 123
were premanifest gene-carriers, defined as genetically
confirmed but without clinically evident symptoms,
120 were patients with stage 1 and 2 HD; and 123
were age- and sex-matched healthy controls. Partic-
ipants were recruited from four study sites: London
(UK), Paris (F), Vancouver (CAN), and Leiden (NL).
Premanifest participants were included only if they
did not have substantial motor signs as indicated by
total motor scores of ≤5 points on the Unified Hunt-
ington’s Disease Rating Scale [UHDRS; 42], and if
they had Disease Burden Scores of at least 250 [43].
For each premanifest gene-carrier, we computed an
estimate of the proximity (in years) to predicted dis-
ease onset based on CAG repeat length and current
age [44]. Then, using a median split (10.8 years to
expected onset) we created a further from estimated
onset group (PreHD-A, >10.8 years to estimated onset)
and a closer to estimated onset group (PreHD-B, <10.8
years to estimated onset). For early stage HD partici-
pants, we used Total Functional Capacity (TFC) scores
from the UHDRS to differentiate between those in
the HD stage 1 group (HD1, TFC scores 11–13) and
HD stage 2 group (HD2, TFC scores 7–10) [45]. For
information on the full cognitive assessment battery,
additional examinations and detailed inclusion criteria,
see Tabrizi et al. [3, 9]. In the current report, we report
cross-sectional data from a visual working memory
task, Spot the Change (SPOT).
Spot the Change task
The Spot the Change task (SPOT) was based on a
visual array comparison task [46, 47]. Using a Lenovo
Vantage ThinkPad tablet PC (IBM, New York), partic-
ipants viewed an array of coloured squares (250 ms) on
the screen, followed by a blank display (1000 ms). This
was followed by a second array of coloured squares in
which one of the squares is encircled. The position
of the squares was unchanged between the two pre-
sentations. Participants were asked to indicate if the
colour of the encircled square had changed from the
first to second display. Using a mouse mounted on
a stabilising wooden platform, the response “same”
was to be made using the dominant thumb to indicate
that the encircled square had not changed colour, and
a response of “different” was to be made using the
non-dominant thumb to indicate that the colour of the
encircled square had changed and was therefore ‘dif-
ferent’. “Same” and “Different” labels were attached
to the mouse platform to remind subjects which thumb
corresponded to which response. No feedback was
provided following participant responses. Responses
could be made up to 8 seconds after the beginning of
the second display. Prior to starting the task, instruc-
tions and a minimum of four practice trials were given
to ensure task comprehension.
In order to determine the most sensitive task con-
dition, three levels of difficulty were used which
were based on the number of coloured squares con-
tained in the array. Ranging from easiest to hardest,
they included three coloured squares (set size 3), five
coloured squares (set size 5), and 7 coloured squares
(set size 7). Data from the three set sizes were col-
lected at two different visits separated by 12-months.
Set sizes 3 and 5 were collected at visit 1 (baseline),
and set size 7, along with set size 5 again, were col-
lected at visit 2 (12-month follow-up). Each set size
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consisted of 32 trials, and stimuli were presented at
random. At the 12-month follow-up visit, set size 3 was
excluded because the baseline results showed ceiling
effects, and as a result we introduced a more difficult
condition, set size 7. This paper is reporting on cross-
sectional data from set sizes 3 and 5 (collected at visit
1) and set sizes 5 and 7 (collected at visit 2). Longitudi-
nal data for set size 5 has been reported in our previous
report; see Tabrizi and colleagues [3]. Accuracy and
response time were recorded and analysed separately
for each of the set sizes.
Non-response trials were recorded when a partici-
pant did not respond within the given 8-second time
frame, which occurred 168 times across the groups
for both visits and all set sizes (0.38% of the trials).
In an additional seven trials, responses were given
within 100 ms of the stimulus; these were considered
to be ‘pre-cognitive’ or accidental responses and were
excluded from the analysis. Accuracy measures were
corrected for guessing by the calculation of k; a mea-
sure of working memory capacity as described by
Cowan [46]. It is computed as k = set size n ([num-
ber correct hits/number of trials] + [number correct
rejections/number of trials]−1). A k (working mem-
ory capacity) value close to the set size (e.g., 3, 5 or 7)
indicates good working memory capacity, whereas a k
value close to or less than zero represents performances
closer to chance.
Of the subjects that attended the visits, only a small
number of participants failed to complete the Spot the
Change task, which was nearly always due to time con-
straints. The task was completed at visit 1 (baseline),
visit 2 (12-month follow-up), or at both visits by a
total of 363/366 (99%) participants (with 1 control and
2 HD2 participants not completing the task at any of
the visits and were thus excluded from the analysis).
Visit 1 had a total of 355 of 366 who completed the task
(97%), yielding missing data for 3 controls, 5 HD1, and
3 HD2. Of the 355 (92%) participants at visit 1, 325
participants returned for visit 2, with an additional 8
completing the task who did not do so at visit 1. There-
fore, 333 out of 366 (91%) completed the task during
visit 2, yielding missing data for 9 controls, 1 PreHD-
A, 5 PreHD-B, 6 HD1 and 12 HD2 during this visit.
Statistical analysis
All analyses were performed using SAS v9.2 (Stata
Corporation, College Station, Texas). The working
memory capacity (k) data were analysed in a single
regression model incorporating data from the three
difficulty levels and both visits. Working memory
capacity (k) was the outcome variable of interest.
The main predictors were group (controls, PreHD-A,
PreHD-B, HD1 and HD2) and set size at each visit (set
sizes 3 and 5 at visit 1 and set sizes 5 and 7 at visit 2).
Response times (RT) were considered separately for
correct (correct recognitions and correct rejections) or
incorrect (incorrect recognitions and incorrect rejec-
tions) trials. The distributions of RTs were highly
skewed and therefore were log transformed prior to
analysis to improve normalisation of these variables for
statistical analysis. Similar to the analyses for working
memory capacity, all RT data from both visits and from
all three set sizes were analysed in a separate single
regression model with RT as the outcome. The main
predictors were group (controls, PreHD-A, PreHD-B,
HD1 and HD2), response accuracy (correct or incor-
rect) and set size (set sizes 3 and 5 at visit 1 and set
sizes 5 and 7 at visit 2).
Age, gender, education level and study site were
included as covariates for both the working memory
capacity (k) and RT models. The regression mod-
els used generalised estimating equations, which have
a working assumption of exchangeability and robust
standard errors [48, 49]. This allowed for cross-
sectional comparison of each gene-carrier group to
controls for each set size. We also examined whether
groups responded differently in terms of RTs for cor-
rect versus incorrect trials.
Finally, to examine the direct relationship between
accuracy and RT, we computed separate linear regres-
sion models for each set size with the mean of the log
transformed RTs for each individual as the outcome
measure. Because interactions require larger samples
we collapsed the five groups into three groups which
included controls, a premanifest group (PreHD-A and
PreHD-B combined) and an early HD group (HD1 and
HD2 combined). For this analysis, k and group (con-
trols, PreHD, and early HD) were the main predictors.
Again, age, gender, education level and study site were
covariates. A group versus k interaction was included to
allow for differences in the speed/accuracy relationship
between groups to be investigated.
RESULTS
To address our primary objective of examining
visual working memory, here we first describe k (work-
ing memory capacity) for each set size (3, 5 and 7) in
the five groups (controls, PreHD-A, PreHD-B, HD1
and HD2). We then present RT findings per set size
across five groups. Finally, we describe the relationship
between RT and accuracy to further characterise the
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nature of visual working memory using three groups
(controls, PreHD and early HD).
Working memory capacity (k) was significantly
lower for the PreHD-B, HD1 and HD2 groups at each
visit for each set size (3, 5 and 7) compared to healthy
controls (Table 1 and Fig. 1a and b). PreHD-A did
not show a difference to controls for any set size at
either visit. Set size 3 demonstrated a ceiling effect in
controls and both premanifest groups (PreHD-A and
PreHD-B), but this ceiling effect was not apparent for
set sizes 5 and 7.
The RTs in the easiest condition, set size 3, were
slower in the PreHD-B, HD1 and HD2 than in con-
trols when answering correctly, despite the ceiling
effect (Table 1 and Fig. 1c). For set size 3 incor-
rect responses, only the HD2 group was significantly
slower than controls. The response times for correct tri-
als on set size 5 (the moderately difficult trials) showed
a relatively consistent pattern across visits, with the
PreHD-A looking most similar to controls, followed
by the PreHD-B group and then HD1 and HD2, with
greatest slowness in the most advanced group (HD2).
In contrast, response times for incorrect trials on set
size 5 showed a less consistent pattern; see Table 1
and Fig. 1c, d. In the most challenging condition, set
size 7, all four clinical groups (PreHD-A, PreHD-B,
HD1 and HD2) were significantly slower than controls
when responding correctly, but when responding incor-
rectly, only HD1 and HD2 were slower; see Table 1 and
Fig. 1d.
Overall, across all set sizes (3, 5, and 7) response
times for correct responses showed more consistent
results across groups such that the PreHD-A group
looked more similar to controls, followed by the
PreHD-B group, and then the HD1 and HD2 groups.
In contrast, the responses time for incorrect responses
showed less consistency in these relationships. A sta-
tistically significant interaction between HD group and
response accuracy (see p values in the rightmost col-
umn of Table 1) indicates that the magnitude of the
difference between the RT in correct trials and the RT
in incorrect trials (i.e., estimated RT for incorrect tri-
als minus estimated RT for correct trials) for the group
in question was different to the magnitude of this RT
difference in controls. For set size 5, for example, the
magnitude of the difference in RTs between correct and
incorrect trials was found to be different from that in
controls for both HD1 and HD2 at both visit 1 and visit
2 (p<0.001 in all cases). These interactions are clearly
illustrated in Figs. 1c and 1d. For all set sizes and all
HD groups, RTs are larger for incorrect than for cor-
rect responses. However, the difference between mean
RTs for correct and incorrect responses is greatest in
controls and declines with increasing severity of dis-
ease stage, with much less differentiation between RTs
for the two response categories in the HD1 and HD2
groups, especially for set sizes 5 and 7.
In a separate analysis of the relationship between
speed and accuracy, we found no evidence for a rela-
tionship between speed of response and accuracy for
any of the set sizes in either controls or the premanifest
gene-carrier group. In contrast, we did find that slower
response times were related to lower accuracy levels in
the manifest early HD group for all set sizes. Specif-
ically, longer RTs were associated with less accurate
responses at visit 1 for set sizes 3 and 5, and at visit 2
for set sizes 5 and 7 (all p-values <0.001; see Fig. 1e).
DISCUSSION
This study’s main findings were two-fold. Firstly,
when compared to controls, visuospatial working
memory capacity and response times were found to
be poorer in both premanifest HD gene-carriers who
were within a decade of disease onset, and those in the
early stages of HD. Secondly, in manifest HD, despite
observing both poor working memory capacity and
slower response times, the relationship between motor
response speed and accuracy did not indicate a speed-
accuracy trade-off, but rather we observed that longer
response times corresponded to poorer performance.
From these results we conclude that working mem-
ory capacity is impaired in premanifest gene-carriers
close to expected disease onset (i.e., within 10.8 years
of expected diagnosis) and in stage 1 and 2 HD patients
as compared to healthy controls. This is consistent
across all set sizes (3, 5, and 7) and both visits. These
findings confirm the presence of dysfunction in visual
working memory which has previously been found in
HD patients in cross-sectional studies [13, 50], and
now extends these findings to premanifest HD. In
the previously reported TRACK-HD study [9], cross-
sectional findings on group differences for working
memory capacity were reported for adjacent groups
(e.g., PreHD-A vs. PreHD-B and PreHD-B vs. HD1)
and not for every clinical group as compared to con-
trols as was done in the current study. In their only
comparison to controls, the authors found a significant
difference on accuracy between controls and the near
from onset premanifest group [9], which is similar to
the current findings. Furthermore, the task used in the
current study required various levels of working mem-
ory capacity as demonstrated by the three set sizes;
102 E.M. Dumas et al. / Working Memory in HD
6
4
2
0
-2
-4
6
4
2
0
-2
-4
2200
6
Controls Premanifest HD Early HD
Correct 5s
Correct 7s
Incorrect 5s
Incorrect 7s
Correct 3s
Correct 5s
Incorrect 3s
Incorrect 5s
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
6
4
2
0
-2
-4
500 1000 1500 2000 2500 3000 3500500 1000 1500 2000 2500 3000 3500
500 1000 1500 2000 2500 3000 3500 500 1000 1500 2000 2500 3000 3500
500 1000 1500 2000 2500 3000 3500500 1000 1500 2000 2500 3000 3500
500 1000 1500 2000 2500 3000 3500
500 1000 1500 2000 2500 3000 3500
Mean response time (ms) Mean response time (ms)
Mean response time (ms)Mean response time (ms)Mean response time (ms)
Mean response time (ms)
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
Vi
si
t 2
 - 
Se
t S
ize
 7
Vi
si
t 2
 - 
Se
t S
ize
 5
Vi
si
t 1
 - 
Se
t S
ize
 5
Ac
cu
ra
cy
 (k
)
Ac
cu
ra
cy
 (k
)
R
es
po
ns
e 
tim
e 
(m
s)
R
es
po
ns
e 
tim
e 
(m
s)
W
o
rk
in
g 
m
em
or
y 
ca
pa
cit
y 
(k)
W
o
rk
in
g 
m
em
or
y 
ca
pa
cit
y 
(k)
Mean response time (ms) Mean response time (ms) Mean response time (ms)
500 1000 1500 2000 2500 3000 3500
2000
1800
1600
1400
1200
Ctrl
Ctrl
PreA
PreA
PreB
PreB
HD1
HD1
Visit 1–Set Size 3 Visit 1–Set Size 5 Visit 1–Set Size 7Visit 2–Set Size 5
HD2
HD2 Ctrl PreA PreB HD1 HD2 Ctrl PreA PreB HD1 HD2Ctrl PreA PreB HD1 HD2
Ctrl
2200
2000
1800
1600
1400
1200
PreA PreB HD1 HD2
a b
c d
e
Fig. 1. Working memory capacity for set sizes 3 and 5 at visit 1 (a), and set sizes 5 and 7 at visit 2 (b) for HD gene-carriers and healthy
controls. Response time for set sizes 3 and 5 at visit 1 (c) and set sizes 5 and 7 at visit 2 (d). Speed vs. accuracy for set sizes 5 and 7 (e) in
controls, premanifest gene-carriers (PreHD) and patients (set size 3 not shown due to ceiling effect in controls and premanifest gene-carriers).
Ctrl = healthy controls, PreA = premanifest gene-carriers far from expected disease onset, PreB = premanifest gene-carriers close to expected
disease onset, HD1 = patients in stage 1 of the disease, HD2 = patients in stage 2 of the disease, Visit 1 = baseline visit, Visit 2 = 12-month visit.
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Table 1
Participant characteristics and adjusted differencesa in working memory capacity and response time for set sizes 3, 5 and 7 for HD gene-carriers
compared to controls
Number of Female/male Age (years)b Education CAG repeat Expected years Disease duration
participants levelc length to onsetb (years)b
n n mean (SD) mean (SD) mean (SD) mean (SD) mean (SD)
Controls 122 68/54 46.2 (10.1) 4.0 (1.3) – –
PreHD-A 62 33/29 41.1 (8.6) 4.1 (1.1) 42.1 (1.8) 14 (3.1) –
PreHD-B 58 33/25 40.6 (9.2) 3.8 (1.3) 44.2 (2.5) 9 (1.3) –
HD1 77 46/31 47.2 (10.3) 3.8 (1.3) 43.8 (3.3) – 5 (5.8)
HD2 44 19/25 51.0 (8.6) 3.3 (1.4) 43.5 (2.4) – 8 (4.5)
Working memory capacity (k) Response time (% increase)d
Correct Incorrect Interactione
Est. 95% CI p Est. 95% CI P Est. 95% CI p p
Visit 1 –
Set size 3
PreHD-A –0.04 (–0.26 to 0.18) 0.70 2.6% (–2.6 to 8.2) 0.33 0.8% (–8.7 to 11.3) 0.88 0.66
PreHD-B –0.26 (–0.44 to –0.07) 0.01 7.6% (1.6 to 13.9) 0.01 8.1% (–3.8 to 21.4) 0.19 0.93f
HD1 –0.78 (–1.01 to –0.54) <0.001 18.9% (10.9 to 27.4) <0.001 7.3% (–2.8 to 18.3) 0.16 0.004
HD2 –0.95 (–1.25 to –0.65) <0.001 39.4% (27.0 to 53.1) <0.001 30.9% (17.7 to 45.6) <0.001 0.09
Visit 1 – Set
size 5
PreHD-A –0.26 (–0.61 to 0.09) 0.14 4.6% (–1.2 to 10.8) 0.12 4.9% (–4.3 to 15.0) 0.31 0.94f
PreHD-B –0.71 (–1.04 to –0.37) <0.001 8.3% (1.6 to 15.5) 0.02 2.5% (–7.2 to 13.2) 0.63 0.13
HD1 –1.38 (–1.71 to –1.04) <0.001 14.9% (7.2 to 23.3) <0.001 1.6% (–7.4 to 11.4) 0.74 <0.001
HD2 –1.45 (–1.84 to –1.06) <0.001 40.1% (27.7 to 53.6) <0.001 22.2% (8.5 to 37.5) 0.001 <0.001
Visit 2 – Set
size 5g
PreHD-A –0.03 (–0.31 to 0.26) 0.87 3.1% (–2.2 to 8.6) 0.26 10.6% (3.0 to 18.7) 0.005 0.005f
PreHD-B –0.78 (–1.19 to –0.36) <0.001 4.1% (–2.3 to 10.9) 0.21 1.2% (–8.6 to 12.1) 0.82 0.40
HD1 –1.38 (–1.72 to –1.03) <0.001 21.0% (13.4 to 29.2) <0.001 10.7% (2.9 to 19.2) 0.007 <0.001
HD2 –1.92 (–2.40 to –1.43) <0.001 37.1% (23.6 to 52.0) <0.001 19.4% (6.3 to 34.1) 0.003 <0.001
Visit 2 – Set
size 7
PreHD-A –0.05 (–0.50 to 0.41) 0.85 5.5% (–0.1 to 11.3) 0.05 3.6% (–3.5 to 11.3) 0.33 0.40
PreHD-B –1.10 (–1.62 to –0.59) <0.001 7.3% (0.2 to 14.9) 0.04 –0.9% (–9.4 to 8.4) 0.84 0.002
HD1 –1.38 (–1.83 to –0.93) <0.001 24.2% (15.8 to 33.1) <0.001 10.5% (2.3 to 19.3) 0.01 <0.001
HD2 –2.01 (–2.56 to –1.45) <0.001 35.1% (23.4 to 48.0) <0.001 17.4% (5.2 to 31.0) 0.004 <0.001
aAll results are adjusted for age, sex, educational level and study site; bAge, expected years to onset and disease duration as at baseline;
cEducation level as a proxy for Intelligence Quotient, as based on the ISCED education classification system; dFor ease of interpretation, the log
RT values were back-transformed to the original millisecond scale and these results were reported; eThe interaction represents the difference
in estimated RTs for correct and incorrect responses for each HD subgroup compared with the same difference in Controls; f The difference in
estimated RT for correct and incorrect responses is larger in the HD subgroup than the difference in controls. In all other cases the difference in
RT for correct and incorrect responses is smaller in the HD subgroup than the difference in controls. gLongitudinal outcomes for set size 5 is
reported elsewhere; see Tabrizi et al. [3].
results indicating lower working memory capacity at
all levels of task difficulty.
Response time results indicated that premanifest and
early stage HD participants were slower than controls
when responding correctly to the task trials. This is
particularly relevant as the premanifest gene-carrier
group were restricted to those who were free of clini-
cally evident motor signs. Given the lack of significant
motor signs in this group, we believe that the slower
response times observed may indicate slowed cog-
nition or information processing rather than slowed
motor processing. Our finding is consistent with
previous findings of psychomotor slowing in preman-
ifest groups [8, 22]. We also note that the working
memory task included a long response time frame (8
seconds), to allow participants, even those with early
HD who have proven motor deficits, to respond to the
trials within the time frame. The task design there-
fore eliminated any potential differences in response
times being attributed to missing data in the early
HD group. Not surprisingly, the differences between
response times for correct and incorrect trials (at each
set size) were greatest in the control group and the
PreHD-A group, whereas with greater levels of the
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disease, this differentiation in response times broke
down.
A key strength of the current paper is that by
examining speed and accuracy together, we can fur-
ther understand how slowing and accuracy are related
within a working memory task. In previous studies
however, psychomotor speed and working memory
have been examined in separate tasks. In premani-
fest gene-carriers and controls, we found that response
times and working memory capacity were not signifi-
cantly related to each other. More specifically, we did
not find evidence for a speed-accuracy trade-off in any
participant group. A speed-accuracy trade-off would
have been apparent if faster responders showed less
accuracy than slower responders [51]. On the contrary,
we found evidence that in early stage HD the oppo-
site is true, such that slower responses were associated
with less accurate performances and thus lower visual
working memory capacity.
Similar to longitudinal (12-month) results previ-
ously reported [3], our findings suggest that poor
visuospatial working memory in early HD is char-
acterised by both slower responses times and lower
accuracy. This kind of relationship or co-occurrence
of slow speed and low accuracy could be termed
the “worse-worse phenomenon”. That is, although the
premanifest gene-carriers demonstrated significantly
slower response times as well as a poorer working
memory capacity when compared to controls, there
was no statistical evidence of a relationship between
the two. Because motor slowing can be present at
the same time as poor cognitive performance in the
absence of a relationship between the two, as is seen in
the premanifest gene-carriers, the presence of motor
slowing does not directly implicate it as a primary
cause of poorer cognitive performance. Therefore, the
presence of a “worse-worse phenomenon” indicates
that poor cognitive performance cannot be explained
by slow response times only. These impairments are in
line with the neuropathology of HD whereby regions
implicated in normal working memory processes, that
is, regions of the frontostriatal brain circuit, are also
the key regions implicated in the pathology of HD
which has additional implications for driving of motor
responses [28–31].
A strength of the current study is that the visual
working memory task used in this study included a
reasonably large number of trials, thereby providing
relatively robust estimates of working memory capac-
ity across three difficulty levels. The task can be argued
to assess visuospatial rather than verbal working mem-
ory because it uses a random selection of colours and
location of squares between trial pairs, which makes
the use of verbal encoding strategies unlikely. In addi-
tion, this design also appears to have minimal practice
effects.
One limitation is that it is not possible to elimi-
nate deficits in basic attention as a cause for poor task
performance. However, the short trial duration was
designed to limit the impact of short attention spans
on task performance. It is also important to realise
that attentional functions are interlinked with working
memory, and the role of attention in cognitive pro-
cessing is complex. In fact, Cowan [46] argued that
working memory tasks, such as the Spot the Change
task, assess the scope of attention, a key factor that lim-
its working memory capacity. As HD progresses, there
may be a decrease in the ability to adequately attend
to and extract relevant information from the task at
hand. Therefore, although attention span is not directly
assessed by this task, attention processes play a role in
the task outcome. This could be reflected in the “worse-
worse phenomenon” whereby it may be more difficult
for patients with HD to extract the needed information
from the stimuli, as well as being slower at integrating
the information from the first and second arrays.
It is important to note that this report solely
addressed cross-sectional findings. Inferences about
longitudinal effects cannot be made with certainty.
Another consideration with regard to generalisabil-
ity of our findings is that premanifest samples across
studies can vary considerably, and thus the specific
characteristics of the sample should be taken into
account in the interpretation of the results. For exam-
ple, our study, while it included premanifest subjects
with relatively high disease burden, it excluded pre-
manifest subjects with subtle motor signs by restricting
the UHDRS motor score to 5 or less. Other sam-
ples, such as in PREDICT-HD, included premanifest
samples regardless of motor scores. Because the pres-
ence of motor signs is more indicative of approaching
disease diagnosis, it is likely that the PREDICT-HD
sample is relatively closer to disease diagnosis on aver-
age than our TRACK-HD sample. The decision to
exclude premanifest subjects with subtle motor signs
from the TRACK-HD sample was made to allow for the
investigation of cognitive impairments in the relative
absence of motor signs in the premanifest period.
In summary, we conclude that visual working mem-
ory impairment can be detected in both premanifest
gene-carriers and early stage HD patients using the
Spot the Change task. In early stage HD, we observed a
“worse-worse phenomenon” whereby lower accuracy
was associated with slower responses, the opposite
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of a speed-accuracy trade-off. Our findings, together
with other reports in the literature, suggest that work-
ing memory tasks are useful markers of cognitive
deterioration in HD. Such deterioration may be most
sensitively detected in early HD, especially stage
2, using moderate to higher working memory loads
along with measures of working memory capacity and
response times for correct trials. This sort of cog-
nitive task may be applicable in short term clinical
trials (of 12 or more month duration) of disease mod-
ifying or symptomatic treatments for participants in
stage 2 HD. Future examination of longitudinal effects
in the most difficult condition, set size 7, once such
data become available from the TRACK-HD study,
may reveal added task sensitivity for premanifest gene-
carriers or stage 1 HD.
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